FAQ: ADCs in NSCLC
Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer

Released: March 17, 2021

Expiration: March 16, 2022

D. Ross Camidge
D. Ross Camidge, MD, PhD
Joel W. Neal
Joel W. Neal, MD, PhD

Activity

Progress
1
Course Completed

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC. 

Presenters:

Ross Camidge, MD, PhD  
Professor of Medicine/Oncology  
University of Colorado Cancer Center
Aurora, Colorado

Joel W. Neal, MD, PhD  
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California